A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Latest Information Update: 08 May 2024
At a glance
- Drugs Palifermin (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 29 Nov 2015 New trial record